Allogeneic T-cell Immunotherapy Company - Atara Biotherapeutics Atara is an allogeneic T-cell immunotherapy company We're harnessing the natural biology of T cells—our body’s most effective weapon in fighting disease—to develop transformative therapies for patients with cancer and autoimmune conditions
Atara Biotherapeutics (ATRA) Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory
Careers - Atara Biotherapeutics - Atara Biotherapeutics When people ask about your career with Atara, your answer will be compelling Because we’re a pioneer in T-cell immunotherapy, leveraging our novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases, including cancer and autoimmune diseases
Technology - Atara Biotherapeutics As a leading allogeneic T-cell immunotherapy company, Atara is pioneering the development of transformative therapies for patients with serious diseases by leveraging our novel allogeneic Epstein Barr virus (EBV) T-cell platform
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO . . . Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory
Press Releases :: Atara Biotherapeutics (ATRA) Atara Biotherapeutics Announces U S FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease